
Navin Kumar Chintala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9206202/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell, 2019, 36, 471-482.	16.8	280
2	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab. Cancer Discovery, 2021, 11, 2748-2763.	9.4	222
3	Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche. Cancer Research, 2014, 74, 3454-3465.	0.9	151
4	Pulmonary Alveolar Macrophages Contribute to the Premetastatic Niche by Suppressing Antitumor T Cell Responses in the Lungs. Journal of Immunology, 2015, 194, 5529-5538.	0.8	131
5	Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Current Opinion in Immunology, 2018, 51, 103-110.	5.5	88
6	Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent Journal of Clinical Oncology, 2019, 37, 2511-2511.	1.6	75
7	Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. Journal of Thoracic Oncology, 2018, 13, 16-26.	1.1	72
8	The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1. Journal of Immunology, 2017, 198, 2989-2999.	0.8	63
9	Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. Nature Protocols, 2021, 16, 1331-1342.	12.0	48
10	Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. , 2019, , .		38
11	CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. Lung Cancer, 2021, 157, 48-59.	2.0	16
12	Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 89-102.	1.1	16
13	Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy. Frontiers in Oncology, 2019, 9, 1042.	2.8	10
14	Novel immunotherapy clinical trials in malignant pleural mesothelioma. Annals of Translational Medicine, 2017, 5, 245-245.	1.7	6
15	Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis. Journal of Visualized Experiments, 2016, , .	0.3	4
16	MA11.01 Comparative Efficacy of T-Cell Intrinsic Versus Extrinsic PD-1 Blockade to Overcome PD-L1+ Tumor-Mediated Exhaustion. Journal of Thoracic Oncology, 2018, 13, S392.	1.1	4
17	MA06.06 An Ex-Vivo Patient-Derived, Immunocompetent (PDI) Culture System to Evaluate Immunotherapeutic Agents' Anti-Tumor Efficacy. Journal of Thoracic Oncology, 2018, 13, S376.	1.1	3
18	Immunotherapy for thoracic malignancies. Indian Journal of Thoracic and Cardiovascular Surgery, 2018, 34, 54-64.	0.6	0

#	Article	IF	CITATIONS
19	MA12.07 gC1qR Expression is Independently Prognostic for Survival Benefit Following Chemotherapy in Mesothelioma. Journal of Thoracic Oncology, 2018, 13, S398.	1.1	0
20	MA05.03 Immune Microenvironment and its Association with Adjuvant Chemotherapy Benefit in Locoregionally Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology, 2018, 13, S371.	1.1	0